로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Cell > DLL3 > SCCHO-ATP111

CHO/Human DLL3 Stable Cell Line Development Service

  • Description
    The CHO/Human DLL3 Stable Cell Line was engineered to express the receptor full length human DLL3 (Gene ID: 10683), used to mimic cancer target cells. Surface expression of Human DLL3 was confirmed by flow cytometry.
  • Application

    • Useful for cell-based DLL3 binding assay

  • Growth Properties
    Adherent
  • Selection Marker
    Puromycin (2 μg/mL)
  • Culture Medium
    F-12K + 10% FBS
  • Freeze Medium
    Serum-free cell cryopreservation medium
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
Receptor Assay
 DLL3 FACS

Expression analysis of human DLL3 on CHO/Human DLL3 Stable Cell Line by FACS.
Cell surface staining was performed on CHO/Human DLL3 Stable Cell Line or negative control cell using anti-human DLL3 antibody followed by staining with PE anti-human IgG Fc Antibody.

Please contact us if you are interested in related cell pool service.

  • Background
    Delta-like protein 3 (DLL3) is a transmembrane protein that belongs to the Delta/Serrate/Lag-2 (DSL) family of Notch ligands.May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm. DLL3 protein is expressed on the surface of tumor cells but not in normal adult tissues.
  • Permits & Restrictions
    This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
  • Clinical and Translational Updates

코멘트 (0)


재고상품 출발날짜: 영업일 기준 4일

가격(KRW) : 5,250,000

보급 및 전시



약물 개발 현황

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:13 Details
  • Latest Research Phase:NDA/BLA

Datasheet & Documentation

관련 제품

신제품

문의와 컨텐츠

This web search service is supported by Google Inc.

totop